Effects of desipramine on prazosin potency at α1A- and α1D-adrenoceptors in rat vas deferens: Implications for the α1L-adrenoceptor subclassification

What makes the α1A‐adrenoceptor gene product assume an α1L‐adrenoceptor phenotype?

“…Such changes might be as simple as the use of different animal species or strains, buffers or incubation times for antagonists, or other protein inhibitors. Indeed, the argument has been put forward that the range of prazosin potencies and receptor subtypes reported in rat vas deferens may be explained by the choice of cocaine or desipramine employed as a noradrenaline transporter blocker (Docherty, ). Similarly, the choice of agonist and whether a discrete or cumulative protocol for the addition of agonists is employed for the construction of concentration–response curves may also produce differences in the determination of antagonist affinities.…”

“…Such changes might be as simple as the use of different animal species or strains, buffers or incubation times for antagonists, or other protein inhibitors. Indeed, the argument has been put forward that the range of prazosin potencies and receptor subtypes reported in rat vas deferens may be explained by the choice of cocaine or desipramine employed as a noradrenaline transporter blocker (Docherty, 2014).…”